> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Symbiomix Antibiotic for Vaginosis
- URL: https://www.fdaweb.com/fda-approves-symbiomix-antibiotic-for-vaginosis/
- Published: 2017-09-18T12:00:00.000Z
- Updated: 2026-09-14T22:51:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139646

FDA has approved a Symbiomix Therapeutics NDA for Solosec (secnidazole) 2g oral granules for treating bacterial vaginosis (BV) in adult women. The next-generation, 5-nitroimidazole antibiotic is designed with enhanced pharmacokinetic properties that enable delivery in a single dose, according to the company.

Approval was based on data from two pivotal trials in BV and an open label safety study, which found efficacy for a single-dose of secnidazole 2g, Symbiomix says. All treatment-emergent adverse events were mild or moderate in intensity, and no serious adverse events were reported, it adds.